In Development
Open for Enrollment

Key

Enrollment on Hold

12/9/2016

Myeloproliferative Neoplasms (MPN)

- CNL/atypical CML
  - IRB#10262
    - Oral Ruxolitinib for CNL or atypical CML.

- Myelofibrosis
  - IRB#16363
    - Phase 2
    - INCB050465 plus Ruxolitinib

- IRB#15977
  - Non Treatment National MDS Study (ECOG/ACRIN)

www.ohsu.edu/cancer